Bell Rose Capital Inc., a company operating within the Consumer Discretionary sector, specifically in the Specialty Retail industry, is a U.S.-based entity primarily engaged in the production and marketing of pharmaceuticals. The company’s focus is on developing treatments for viral infections, notably Hepatitis C and HIV/AIDS. In addition to its pharmaceutical endeavors, Bell Rose Capital Inc. provides anti-viral therapy research and development services.
The company is listed on the OTC Bulletin Board, having made its Initial Public Offering (IPO) on April 10, 1995. As of February 18, 2026, Bell Rose Capital Inc.’s shares closed at $0.0007. Over the past year, the stock has experienced significant volatility, with a 52-week high of $1.50 on February 20, 2025, and a 52-week low of $0.0001 on February 3, 2026. This volatility indicates a range of 15,000%, highlighting the stock’s limited liquidity and susceptibility to substantial price fluctuations. The current market capitalization stands at $2,470,000 USD.
In terms of recent developments, the most current public update from Bell Rose Capital Inc. dates back to October 29, 2025. During this update, CEO Carlos Salgado announced the launch of LENIE, an AI-powered logistics platform. This initiative represents the company’s efforts to integrate advanced technology into its operations, potentially enhancing its logistical capabilities.
Despite the absence of recent press releases, the introduction of LENIE underscores Bell Rose Capital Inc.’s commitment to innovation within its industry. However, the stock’s proximity to its annual low suggests that investors may remain cautious, given the company’s current market position and the broader trading environment.
